Shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) saw unusually-high trading volume on Wednesday . Approximately 6,173,077 shares traded hands during mid-day trading, an increase of 1,502% from the previous session’s volume of 385,221 shares.The stock last traded at $4.59 and had previously closed at $4.48.
FOMX has been the topic of a number of research reports. HC Wainwright set a $11.00 target price on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 8th. Cantor Fitzgerald initiated coverage on shares of Foamix Pharmaceuticals in a research note on Thursday, October 11th. They set an “overweight” rating for the company. Zacks Investment Research raised shares of Foamix Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a research note on Wednesday, September 19th. BidaskClub cut shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. Finally, ValuEngine cut shares of Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. Foamix Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $8.25.
The company has a market capitalization of $225.22 million, a P/E ratio of -2.61 and a beta of 2.10.
Foamix Pharmaceuticals (NASDAQ:FOMX) last released its quarterly earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.10. Foamix Pharmaceuticals had a negative net margin of 2,085.71% and a negative return on equity of 131.84%. The firm had revenue of $0.96 million during the quarter, compared to analysts’ expectations of $1.10 million. As a group, sell-side analysts anticipate that Foamix Pharmaceuticals Ltd will post -1.64 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. A.R.T. Advisors LLC purchased a new position in shares of Foamix Pharmaceuticals during the 1st quarter worth about $104,000. Senzar Asset Management LLC purchased a new position in shares of Foamix Pharmaceuticals during the 2nd quarter worth about $338,000. ARK Investment Management LLC boosted its position in Foamix Pharmaceuticals by 17.7% in the 2nd quarter. ARK Investment Management LLC now owns 106,243 shares of the specialty pharmaceutical company’s stock valued at $532,000 after buying an additional 15,980 shares during the period. Wells Fargo & Company MN boosted its position in Foamix Pharmaceuticals by 31.7% in the 3rd quarter. Wells Fargo & Company MN now owns 132,900 shares of the specialty pharmaceutical company’s stock valued at $761,000 after buying an additional 32,013 shares during the period. Finally, Handelsbanken Fonder AB boosted its position in Foamix Pharmaceuticals by 7.0% in the 2nd quarter. Handelsbanken Fonder AB now owns 390,000 shares of the specialty pharmaceutical company’s stock valued at $1,954,000 after buying an additional 25,500 shares during the period. 47.01% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2018/11/07/foamix-pharmaceuticals-fomx-sees-large-volume-increase.html.
About Foamix Pharmaceuticals (NASDAQ:FOMX)
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.
Read More: Why is Cost of Capital Important?
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.